April 9 (Reuters) - EyeGate Pharmaceuticals Inc:
* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL
* IN ITS LETTER, FDA IDENTIFIED FOUR DEFICIENCIES IN COMPANY’S SUBMISSION
* FDA REQUESTED ADDITIONAL INFORMATION ON MANUFACTURING PROCESSES ASSOCIATED WITH EYEGATE OBG PRODUCT
* CO TARGETING SUBMISSION OF A SECOND AMENDMENT TO IDE APPLICATION IN JULY 2018
* IN U.S. FDA’S LETTER, PRIMARY COMMENT RELATES TO VALIDATION OF FILTER SPECIFICALLY USED FOR STERILIZATION OF CMHA MATERIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
